These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 7522954)

  • 61. Direct identification of the murine IL-2 receptor p55-p75 heterodimer in the absence of IL-2.
    Saragovi H; Malek TR
    J Immunol; 1988 Jul; 141(2):476-82. PubMed ID: 3133409
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Interleukin-2 induces tumor necrosis factor-alpha production by activated human T cells via a cyclosporin-sensitive pathway.
    Lorré K; Fransen L; Ceuppens JL
    Eur Cytokine Netw; 1992; 3(3):321-30. PubMed ID: 1353987
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effective induction of human NK cells with OK-432 and further augmentation of their cytolytic function by rIL-2.
    Hu ZL; Kubota E; Imamura H; Katano M; Katsuki T
    Microbiol Immunol; 1994; 38(3):183-90. PubMed ID: 7521509
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
    Ortaldo JR; Frey J; Takeshita T; Sugamura K
    Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
    Meropol NJ; Barresi GM; Fehniger TA; Hitt J; Franklin M; Caligiuri MA
    Cancer Immunol Immunother; 1998 Aug; 46(6):318-26. PubMed ID: 9756416
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.
    Trentin L; Zambello R; Bulian P; Cerutti A; Milani A; Pirone E; Nitti D; Agostini C; Semenzato G
    Br J Cancer; 1994 Jun; 69(6):1046-51. PubMed ID: 8198969
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2.
    Lotzová E; Savary CA; Schachner JR; Huh JO; McCredie K
    Am J Hematol; 1991 Jun; 37(2):88-99. PubMed ID: 2069169
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Human fetal liver-derived CD7+CD2lowCD3-CD56- clones that express CD3 gamma, delta, and epsilon and proliferate in response to interleukin-2 (IL-2), IL-3, IL-4, or IL-7: implications for the relationship between T and natural killer cells.
    Hori T; Phillips JH; Duncan B; Lanier LL; Spits H
    Blood; 1992 Sep; 80(5):1270-8. PubMed ID: 1381242
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12.
    Naume B; Johnsen AC; Espevik T; Sundan A
    Eur J Immunol; 1993 Aug; 23(8):1831-8. PubMed ID: 7688307
    [TBL] [Abstract][Full Text] [Related]  

  • 72. IL-7 induces proliferation of CD3-/low CD4- CD8- human thymocyte precursors by an IL-2 independent pathway.
    Fabbi M; Groh V; Strominger JL
    Int Immunol; 1992 Jan; 4(1):1-5. PubMed ID: 1531763
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Expression of p55 (Tac) interleukin-2 receptor (IL-2R), but not p75 IL-2R, in cultured H-RS cells and H-RS cells in tissues.
    Hsu SM; Tseng CK; Hsu PL
    Am J Pathol; 1990 Apr; 136(4):735-44. PubMed ID: 1691591
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
    Phillips JH; Gemlo BT; Myers WW; Rayner AA; Lanier LL
    J Clin Oncol; 1987 Dec; 5(12):1933-41. PubMed ID: 3500280
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
    Arbour S; Toupin S; Bélanger R; Gyger M; Hallé JP; Perreault C; Roy DC
    Bone Marrow Transplant; 1996 Mar; 17(3):315-22. PubMed ID: 8704680
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
    Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
    Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
    Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
    Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
    Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
    Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Relationship of large and small CD3- CD56+ lymphocytes mediating NK-associated activities.
    Ortaldo JR; Winkler-Pickett R; Kopp W; Kawasaki A; Nagashima K; Okumura K; Yagita H; Bach FH
    J Leukoc Biol; 1992 Sep; 52(3):287-95. PubMed ID: 1381742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.